151.56

1.41% -2.17

Revolution Medicines Inc (RVMD)

Overview News Price History Option Chain Financials Why RVMD Down? Discussions Forecast

Revolution Medicines Inc stock is traded at $151.56, with a volume of 1.85M. It is down -1.41% in the last 24 hours and up +7.11% over the past month. Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.

Previous Close:

$153.73

Open:

$154.42

24h Volume:

1.85M

Relative Volume:

0.65

Market Cap:

$32.22B

Revenue:

$742.00K

Net Income/Loss:

$-1.37B

P/E Ratio:

-21.43

EPS:

-7.0731

Net Cash Flow:

$-1.07B

1W Performance:

+4.05%

1M Performance:

+7.11%

6M Performance:

+113.86%

1Y Performance:

+290.62%

1-Day Range:

$151.44

$156.25

1-Week Range:

$141.00

$156.25

52-Week Range:

$34.00

$156.25

Revolution Medicines Inc Stock (RVMD) Company Profile

Name

Revolution Medicines Inc

Sector

Healthcare (1108)

Industry

Biotechnology (618)

Phone

650-481-6801

Address

700 SAGINAW DR, REDWOOD CITY, CA

Employee

883

Twitter

Next Earnings Date

2026-05-06

Latest SEC Filings

RVMD's Discussions on Twitter

Compare RVMD vs VRTX, REGN, ARGX, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RVMD Revolution Medicines Inc	151.56	32.68B	742.00K	-1.37B	-1.07B	-7.0731
VRTX Vertex Pharmaceuticals Inc	434.52	110.03B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	638.88	67.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	806.46	50.76B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.45	40.12B	4.29B	577.22M	641.34M	4.2086

Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-16-26	Resumed	Jefferies	Buy
Feb-27-26	Resumed	UBS	Buy
Nov-18-25	Initiated	Wolfe Research	Outperform
Nov-03-25	Initiated	RBC Capital Mkts	Outperform
Oct-21-25	Initiated	Mizuho	Outperform
Oct-16-25	Resumed	Stifel	Buy
Sep-12-25	Resumed	Raymond James	Strong Buy
Sep-05-25	Initiated	Truist	Buy
Aug-19-25	Initiated	Piper Sandler	Overweight
Aug-15-25	Initiated	Wells Fargo	Overweight
Jul-15-25	Initiated	Goldman	Buy
Jul-16-24	Reiterated	Needham	Buy
Jul-12-24	Initiated	Barclays	Overweight
Jul-08-24	Initiated	Jefferies	Buy
Apr-12-24	Reiterated	Needham	Buy
Apr-10-24	Upgrade	Raymond James	Outperform → Strong Buy
Mar-11-24	Initiated	Piper Sandler	Overweight
Jan-05-24	Upgrade	BofA Securities	Neutral → Buy
Jan-04-24	Initiated	Wedbush	Outperform
Nov-16-23	Initiated	Raymond James	Outperform
Feb-28-23	Upgrade	JP Morgan	Neutral → Overweight
Dec-14-22	Initiated	Needham	Buy
Oct-21-22	Initiated	Oppenheimer	Outperform
May-20-22	Initiated	BofA Securities	Neutral
Mar-01-22	Upgrade	Stifel	Hold → Buy
Sep-23-21	Initiated	Stifel	Hold
Aug-12-21	Downgrade	Goldman	Buy → Neutral
May-18-21	Initiated	Goldman	Buy
May-21-20	Initiated	H.C. Wainwright	Buy
Mar-09-20	Initiated	Cowen	Outperform
Mar-09-20	Initiated	Guggenheim	Buy
Mar-09-20	Initiated	JP Morgan	Neutral

View All

Revolution Medicines Inc Stock (RVMD) Latest News

05:15 AM